SCHEMBL20156668

SCHEMBL20156668

CC(C)NCCN(C)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 3/20 0.38
GPR88 Q9GZN0 1/20 0.37
FPR3 P25089 1/20 0.36
FPR2 P25090 1/20 0.36
AAK1 Q2M2I8 1/20 0.35
CA1 P00915 3/20 0.34
CTSK P43235 3/20 0.34
CA2 P00918 2/20 0.34
CA12 O43570 2/20 0.34
CA7 P43166 2/20 0.33
METAP2 P50579 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
PDK2 Q15119 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1652949 0.89 CA14 (0.41) CA14GPR88FPR3FPR2AAK1
SCHEMBL23675651 0.85 CA14 (0.35) CA14GPR88FPR3FPR2AAK1
SCHEMBL12287124 0.84 CA14 (0.40) CA14GPR88FPR3FPR2AAK1
SCHEMBL30999425 0.83 CHRNB2 (0.37) CA14GPR88FPR3FPR2AAK1
SCHEMBL8211164 0.83 CA14 (0.38) CA14AAK1CA1CTSKCA2
SCHEMBL26900686 0.82 CA14 (0.41) CA14GPR88FPR3FPR2AAK1
SCHEMBL18053858 0.82 AAK1 (0.34) CA14GPR88FPR3FPR2AAK1
SCHEMBL381086 0.80 CA14 (0.41) CA14GPR88FPR3FPR2AAK1
SCHEMBL10272309 0.80 GPR88 (0.44) CA14GPR88FPR3FPR2AAK1
SCHEMBL30511031 0.80 FPR3 (0.37) CA14GPR88FPR3FPR2AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034200-A1 Prodrugs of Neurosteroid Analogs and Uses Thereof UNIV EMORY (US) 2025-01-30 US disclosed
WO-2024197317-A2 NEUROSTEROIDS AND PRODRUGS THEREOF EMORY UNIVERSITY (US) 2024-09-26 WO disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
WO-2023086438-A1 PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF EMORY UNIVERSITY (US) 2023-05-19 WO disclosed
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof Beijing Adamadle Biotechnology Limited Liability Company (CN) 2022-06-07 US disclosed
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof Beijing Adamadle Biotechnology Limited Liability Company (CN) 2022-06-07 US disclosed
EP-3538510-B1 PROCESS FOR THE PREPARATION OF MONO-PROTECTED ALPHA,OMEGA-DIAMINO ALKANES BYONDIS BV (NL) 2021-01-06 EP disclosed
US-10815194-B2 Process for the preparation of mono-protected α,ω-diamino alkanes BYONDIS B.V. (NL) 2020-10-27 US disclosed
EP-3640248-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Adamadle Biotechnology Limited Liability Company (CN) 2020-04-22 EP disclosed
EP-3640248-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Adamadle Biotechnology Limited Liability Company (CN) 2020-04-22 EP disclosed
US-20200087296-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Adamadle Biotechnology Limited Liability Company (CN) 2020-03-19 US disclosed
US-20200087296-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Beijing Adamadle Biotechnology Limited Liability Company (CN) 2020-03-19 US disclosed
WO-2018086993-A1 PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES SYNTHON BIOPHARMACEUTICALS B.V. (NL) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815194-B2 Process for the preparation of mono-protected α,ω-diamino alkanes FCGRT, CD22, DEGS1 CA14 1091/4885GPR88 383/4885FPR3 1506/4885
US-20250034200-A1 Prodrugs of Neurosteroid Analogs and Uses Thereof CYP11B2, CYP11B1, CYP21A2 CA14 1545/4885GPR88 999/4885FPR3 2333/4885
US-20200087296-A1 AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, WEE2, EGFR CA14 4350/4885GPR88 1210/4885FPR3 1959/4885
US-11352352-B2 Aminopyrimidine compound, preparation method therefor and use thereof WEE1, WEE2, EGFR CA14 4350/4885GPR88 1210/4885FPR3 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.